Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Cambridge, MA., June 2, 2022 (BUSINESS WIRE) — Flagship Pioneering, the bioplatform innovation company, andTessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer. Dr. Severino, who was previously Vice Chairman and President of AbbVie, also serves as a Flagship Pioneering CEO-Partner.

“Mike will play a critical role at Flagship as CEO-Partner and, through that position, take on the role as CEO of Tessera, a company revolutionizing genetic medicine”

Dr. Severino brings more than two decades of biopharmaceutical leadership to Tessera, having led the strategy behind research, development, registration, and commercialization of more than a dozen FDA-approved therapies. In his roles at AbbVie as Executive Vice President of Research and Development, Chief Scientific Officer and most recently Vice Chairman and President, he led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology, and neuroscience. Prior to joining AbbVie, Dr. Severino held several senior leadership roles at Amgen, leading to his appointment as Senior Vice President and Corporate Chief Medical Officer where he oversaw the company’s global clinical research efforts.Prior to Amgen, he was Senior Director at Merck & Co., Inc., responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine.

“Mike will play a critical role at Flagship as CEO-Partner and, through that position, take on the role as CEO of Tessera, a company revolutionizing genetic medicine,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Tessera Co-Founder and Board member. “Mike’s R&D expertise and years of experience leading innovative strategies for notable biopharmaceutical companies will help drive Tessera’s growth and the translation of its pioneering technology.”

Afeyan added, “Under Geoff von Maltzahn’s leadership as founding CEO of Tessera, the company has created strong platform foundations and is poised for the next phase of growth as Geoff transitions into the Board Chair role.”

Tessera’s GENE WRITING technology consists of multiple platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Geoffrey von Maltzahn, who served as Tessera’s founding CEO, will transition to Board Chair and continue to stay closely involved in the company’s efforts to transform genetic medicine with treatments for diseases and vulnerabilities through its GENE WRITING platforms.

“Tessera will benefit immensely from Mike’s extensive leadership experience and expertise in both R&D and commercial, especially as we look ahead to bringing GENE WRITING into the clinic,” said Geoffrey von Maltzahn, Ph.D., Co-Founder and Board Chair of Tessera Therapeutics. “I am delighted to welcome Mike to Tessera, and I am confident the company’s GENE WRITING platforms will continue to advance and scale under his leadership.”

“The emerging tools of Genetic Medicine represent a powerful new category of technology that has the potential to change the way we treat human disease and build one of the great companies in our industry,” said Michael Severino, M.D., Flagship Pioneering CEO-Partner and Chief Executive Officer of Tessera Therapeutics. “I am excited by the potential of Tessera’s GENE WRITING platforms and look forward to leading the next phase of our mission to cure disease by writing in the code of life.”

In addition to his CEO role, Dr. Severino will also serve as a director on the company’s board. His appointment reflects Tessera’s continued growth. In the last year, Tessera announced the expansion of its Senior Leadership team with the appointments of Howard Liang, Ph.D., President and Chief Financial Officer; David Davidson, MD., Chief Medical and Development Officer; Michael Holmes, Ph.D., Chief Scientific Officer; Iain McFadyen, Ph.D., Chief Data Officer; and Becky Lillie, Chief Human Resources Officer. In April, Tessera announced that it raised over $300 million in Series C financing to advance its GENE WRITING platforms.



Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases


BD to buy Durham’s Parata Systems for more than $1.5B in cash